Microvolt T-wave alternans complemented with electrophysiologic study for prediction of ventricular tachyarrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy: a long-term follow-up study  

作　　者：She-Liang Xue Xiao-Feng Hou Kang-Yun Sun Yao Wang Zhi-Yong Qian Quan-Peng Wang Si-Peng Shen Hong-Li Yin Rong Zhang Hai-Ping Yin Jian-Gang Zou 

机构地区：[1]Department of Cardiology,The First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China [2]Department of Cardiology,The Affiliated Wujin Hospital of Jiangsu University,Changzhou,Jiangsu 213002,China [3]Department of Cardiology,The Affiliated Suzhou Hospital of Nanjing Medical University,Suzhou,Jiangsu 215008,China [4]Department of Biostatistics,School of Public Health,Nanjing Medical University,Nanjing,Jiangsu 211166,China [5]Key Laboratory of Targeted Intervention in Cardiovascular Disease,Collaborative Inn ovation Center for Cardiovascular Disease Translational Medicine,Nanjing Medical University, Nanjing,Jiangsu 211166,China

出　　处：《Chinese Medical Journal》2019年第12期1406-1413,共8页中华医学杂志（英文版）

基　　金：the National Natural Science Foundation of China (No. 81470457);the Frontier Technology of Jiangsu Provincial Science and Technology Department (No. BE2016764).

摘　　要：Background: The long-term predicted value of microvolt T-wave alternans (MTWA) for ventricular tachyarrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) remains unclear. Our study explored the characteristics of MTWA and its prognostic value when combined with an electrophysiologic study (EPS) in patients with ARVC. Methods: All patients underwent non-invasive MTWA examination with modified moving average (MMA) analysis and an EPS. A positive event was defined as the first occurrence of sudden cardiac death, documented sustained ventricular tachycardia (VT), ventricular fibrillation, or the administration of appropriate implantable cardioverter defibrillator therapy including shock or antitachycardia pacing. Results: Thirty-five patients with ARVC (age 38.6 ± 11.0 years;28 males) with preserved left ventricular (LV) function were recruited. The maximal TWA value (MaxValt) was 17.0 (11.0–27.0)μV. Sustained VT was induced in 22 patients by the EPS. During a median follow-up of 99.9 ± 7.7 months, 15 patients had positive clinical events. When inducible VT was combined with the MaxValt, the area under the curve improved from 0.739 to 0.797. The receiver operating characteristic curve showed that a MaxValt of 23.5 μV was the optimal cutoff value to identify positive events. The multivariate Cox regression model for survival showed that MTWA (MaxValt, hazard ratio [HR], 1.06;95% confidence interval [CI], 1.01–1.11;P = 0.01) and inducible VT (HR, 5.98;95% CI, 1.33–26.8;P = 0.01) independently predicted positive events in patients with ARVC. Conclusions: MTWA assessment with MMA analysis complemented by an EPS might provide improved prognostic ability in patients with ARVC with preserved LV function during long-term follow-up.

关 键 词：Modified moving AVERAGE analysis Microvolt T-WAVE ALTERNANS Electrophysiologic study VENTRICULAR TACHYARRHYTHMIA Arrhythmogenic right VENTRICULAR CARDIOMYOPATHY 

分 类 号：R[医药卫生]